Aethlon Medical To Host Second Quarter Fiscal 2017 Investor Call On November 10, 2016

SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its Second Quarter Fiscal 2017 investor conference call and webcast on Thursday, November 10, 2016 at 4:30 p.m. Eastern Time.

The call and webcast will follow the release of fiscal 2017 second quarter results.  A recorded version of the call will be available approximately two hours after the call at the Investor Relations portion of the company's website, www.aethlonmedical.com.

Interested parties can also access the archived replay of the call webcast at www.aethlonmedical.com in the investor relations section under events & presentations.

Conference Call Details

What: Aethlon's Second Quarter 2017 Investor Conference Call and Webcast

Date: Thursday, November 10, 2016

Time: 4:30 p.m. Eastern Time

Live call: 844-836-8741

International: 412-317-5442

Audio Replay: 412-317-0088

Passcode: 10096196

About Aethlon Medical, Inc.

Aethlon Medical (Nasdaq:AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer.  To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.  Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, Facebook and Google+.

Contacts:

Jim Frakes, CFO
[email protected]
858-459-7800 extension 3300

SOURCE Aethlon Medical, Inc.